A jittery market and hesitant investors befell the biotech sector in the second quarter. For financing, biotech companies are turning increasingly to debt which, excluding public investment in private equities (PIPEs), represented 27% of total funds raised. That's up significantly from the 16% it represented in the first quarter of this year (and could be due to a fall-off in PIPEs). Funding from public offerings and partnership deals did hold up, but it remains to be seen if the IPO window will stay open much longer.
Credit: Source: Multex, BioCentury, Swiss Exchange
Credit: Source: Multex, BioCentury
Credit: Source: BioCentury, Burrill & Company
Credit: Source: BioCentury
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech holds its own in Q2. Nat Biotechnol 22, 938 (2004). https://doi.org/10.1038/nbt0804-938
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0804-938
